• Riccardo Paggi, Anna Barbiero, Tommaso Manciulli, Andreea Miftode, Marta Tilli, Filippo Lagi, Jessica Mencarini, Beatrice Borchi, Marco Pozzi, Filippo Bartalesi, Michele Spinicci, Lorenzo Martini, Alessandra Coppola, Carlo Nozzoli, Adriano Peris, Manuela Bonizzoli, Filippo Pieralli, Alessandro Bartoloni, and Lorenzo Zammarchi.
• Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
• Intern Emerg Med. 2023 Apr 1; 18 (3): 821830821-830.

AbstractMore than 11.5 billion COVID-19 vaccine doses have been administered around the world. Although vaccine effectiveness for severe infections is reported to be 89.0%, breakthrough infections are common and may lead to severe outcome in fragile population. We conducted a real-world observational study on 420 COVID-19 admitted patients from July 2021 to January 2022 in a tertiary level Italian hospital. We collected patient's vaccination and SARS-CoV-2 serological status, SARS-CoV-2 treatments, oxygen supports, intensive (ICU) and subintensive (sub-ICU) care unit admissions, length of staying (LoS) and in-hospital mortality. One-hundred-seventy-two vaccinated and 248 unvaccinated patients were admitted during the study period. Vaccinated group (Vg) had a significantly more elevated Charlson Comorbidity Index than Unvaccinated group (UVg), and no statistical differences were found in terms of in-hospital mortality, LoS or ICU and sub-ICU admissions. Among Vg, anti-S antibodies were detected in 86.18% of patients (seropositives). Vaccinated seronegative patients' in-hospital mortality was significantly higher than vaccinated seropositive patients (33.33% vs 10.69%, p = 0.0055): in particular, mortality rate in 45-69 years old population was higher in vaccinated seronegative group, and comparable in patients ≥ 70 years old. No differences in terms of outcome were registered between Vg and UVg, taking into account that Vg was considerably older and with more comorbidities. In line with other recent observations, higher mortality rate was evidenced for seronegative vaccinated patients. Primary prophylaxis and early treatments result to be necessary, especially for older and immunosuppressed populations.© 2023. The Author(s).

16 keywords...

hide…